Strategic Alliances with Partners in China: Apexigen's Experience
Interview with Xiaodong Yang, M.D., President and CEO, Apexigen, Inc.
240 views
00:04:46 - Uploaded by Song Essinova, LLC on July 27, 2011
In July 2010, Apexigen was spun-out from Epitomics, Inc. with an exclusive, worldwide license to Epitomics' rabbit monoclonal antibody technologies for use in the development and commercialization of therapeutic antibodies. Apexigen will focus on discovering and developing drugs from this proprietary antibody technology platforms, while Epitomics will continue to utilize the technology to develop and commercialize rabbit antibodies for non-therapeutic uses.
At BioPacific 2011 organized by CABS (Chinese-American BioPharmaceutical Society), Xiaodong Yang, M.D., President and CEO of Apexigen explains how alliances with partners in China plays a key role in the new company's development strategy, and reflects on their experience managing the relationships so far.
Tags: China, drug discovery, discovery and development, Apexigen, BioPacific, CABS
RELATED
COMMENTS
There are 0 comments. You must be logged in to comment.
Discovery & Development
-
Emerging Trends and Opportunities in the BioPharmaceutical Industry in China and the US
-
Strategic Alliances with Partners in China: Apexigen's Experience
-
Balancing Aggressiveness and Conservatism
-
US-China Anti-Cancer Association Scholar Award for Cancer Research
-
Expanding Access to Patients in Need Around the World
-
BioPacific 2010 - Drug Discovery and Development in Changing Times
-
China Drug Discovery Landscape
-
China Drug Discovery Landscape
-
Optivia Webinar - Transporter-Enzyme and Transporter-Transporter Interplay in Predicting Drug Absorption and Disposition
-
Location Determines PKC Specificity
-
KAI Selective PKC Inhibitors
-
KAI Selective PKC Activators
-
Epitomics Inc.
